These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28347776)

  • 21. Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer.
    Cura Y; Sánchez-Martín A; Márquez-Pete N; González-Flores E; Martínez-Martínez F; Pérez-Ramírez C; Jiménez-Morales A
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
    van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
    Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gender-dependent association of
    Ioannou C; Ragia G; Balgkouranidou I; Xenidis N; Amarantidis K; Koukaki T; Biziota E; Kakolyris S; Manolopoulos VG
    Pharmacogenomics; 2021 Jul; 22(11):669-680. PubMed ID: 34100299
    [No Abstract]   [Full Text] [Related]  

  • 24. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
    de With M; van Doorn L; Maasland DC; Mulder TAM; Oomen-de Hoop E; Mostert B; Homs MYV; El Bouazzaoui S; Mathijssen RHJ; van Schaik RHN; Bins S
    Biomed Pharmacother; 2023 Mar; 159():114232. PubMed ID: 36630849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
    Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
    J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
    Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
    Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.
    Cortejoso L; López-Fernández LA
    Pharmacogenomics; 2012 Jul; 13(10):1173-91. PubMed ID: 22909207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy.
    Liu D; Li X; Li X; Zhang M; Zhang J; Hou D; Tong Z; Dong M
    Cancer Chemother Pharmacol; 2019 May; 83(5):939-949. PubMed ID: 30877365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of gender on capecitabine toxicity in colorectal cancer.
    Ilich AI; Danilak M; Kim CA; Mulder KE; Spratlin JL; Ghosh S; Chambers CR; Sawyer MB
    J Oncol Pharm Pract; 2016 Jun; 22(3):454-60. PubMed ID: 26002954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
    Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
    Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients.
    Cura Y; Sánchez-Martín A; Márquez-Pete N; González-Flores E; Martínez-Martínez F; Pérez-Ramírez C; Jiménez-Morales A
    Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capecitabine-induced severe adverse events-therapeutic drug monitoring and
    Perera J; Süsstrunk J; Thurneysen C; Steinemann D
    BMJ Case Rep; 2024 Apr; 17(4):. PubMed ID: 38684357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
    Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
    J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenomics of fluorouracil -based chemotherapy toxicity.
    Matsusaka S; Lenz HJ
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):811-21. PubMed ID: 25800061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
    Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
    Lunenburg CA; van Staveren MC; Gelderblom H; Guchelaar HJ; Swen JJ
    Pharmacogenomics; 2016 May; 17(7):721-9. PubMed ID: 27181275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Report of two cases of acute cardiac adverse events in patients with colorectal carcinoma receiving oral capecitabine.
    Lampropoulos S; Roditis P; Koulouris E; Zafiris A; Tzimou M; Kyratlidis K; Pavlidis K; Godwin SA; Kosmas C
    Anticancer Drugs; 2017 Aug; 28(7):801-807. PubMed ID: 28489615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capecitabine pharmacogenetics: historical milestones and progress toward clinical implementation.
    Syn N; Lee SC; Goh BC; Yong WP
    Pharmacogenomics; 2016 Oct; 17(15):1607-1610. PubMed ID: 27676641
    [No Abstract]   [Full Text] [Related]  

  • 40. Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.
    Hamzic S; Kummer D; Milesi S; Mueller D; Joerger M; Aebi S; Amstutz U; Largiader CR
    Clin Pharmacol Ther; 2017 Nov; 102(5):796-804. PubMed ID: 28139840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.